| __timestamp | Cytokinetics, Incorporated | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44426000 | 205018000 |
| Thursday, January 1, 2015 | 46398000 | 392709000 |
| Friday, January 1, 2016 | 59897000 | 299694000 |
| Sunday, January 1, 2017 | 90296000 | 397061000 |
| Monday, January 1, 2018 | 89135000 | 434100000 |
| Tuesday, January 1, 2019 | 86125000 | 782200000 |
| Wednesday, January 1, 2020 | 96951000 | 1119900000 |
| Friday, January 1, 2021 | 159938000 | 2437500000 |
| Saturday, January 1, 2022 | 240813000 | 1560400000 |
| Sunday, January 1, 2023 | 330123000 | 1815800000 |
| Monday, January 1, 2024 | 1970500000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating glimpse into the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and Cytokinetics, Incorporated from 2014 to 2023. Over this period, Regeneron consistently outpaced Cytokinetics, with its cost of revenue peaking at approximately 1.8 billion in 2023, a staggering 780% increase from 2014. In contrast, Cytokinetics saw a more modest rise, with a 640% increase, reaching around 330 million in 2023.
Regeneron's significant growth in cost of revenue reflects its expanding operations and increased production capabilities, likely driven by its successful product pipeline. Meanwhile, Cytokinetics' steady rise indicates a strategic focus on research and development. This data underscores the contrasting strategies of these two biotech leaders, offering valuable insights for those looking to invest in the future of healthcare innovation.
Cost Insights: Breaking Down Amgen Inc. and Regeneron Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Cytokinetics, Incorporated
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Biogen Inc.'s Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Alkermes plc
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Cytokinetics, Incorporated
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Evotec SE's Expenses
Cost Insights: Breaking Down Cytokinetics, Incorporated and Veracyte, Inc.'s Expenses
Cost of Revenue Comparison: Cytokinetics, Incorporated vs HUTCHMED (China) Limited
Cost of Revenue Trends: Cytokinetics, Incorporated vs Iovance Biotherapeutics, Inc.